Newsroom
Sorted by: Latest
-
FFIV INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that F5, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
SAN DIEGO--(BUSINESS WIRE)--The case alleges F5 misled investors with false growth outlooks while hiding a major security breach that risked its reputation and future revenue....
-
Bank of New York Mellon UK Regulatory Announcement: FRN Variable Rate Fix
LONDON--(BUSINESS WIRE)-- As Agent Bank, please be advised of the following rate determined on: 12/22/2025 Issue ¦ NatWest Markets Plc Series No 80 AUD 25,000,000 FRN Due in March 2029 ISIN Number ¦ XS2459477639 ISIN Reference ¦ XS245947763 Issue Nomin AUD ¦ 25000000 Period ¦ 12/22/2025 to 3/23/2026 Payment Date 3/23/2026 Number of Days ¦ 91 Rate ¦ 5.4975 Denomination AUD ¦ 500000 ¦ 25000000 ¦ Amount Payable per Denomination ¦ 6853.05 ¦ 342652.4 ¦ Bank of New York ...
-
Netsmart Strengthens Interoperability Leadership Through CMS Health Technology Ecosystem Pledge
OVERLAND PARK, Kan.--(BUSINESS WIRE)--Netsmart pledges to implement the CMS Interoperability Framework as a CMS Aligned Network, advancing secure, standards-based health data access....
-
Westpac Banking Corporation UK Regulatory Announcement: FRN Variable Rate Fix
LONDON--(BUSINESS WIRE)-- As Agent Bank, please be advised of the following rate determined on: 12/22/2025 Issue ¦ Westpac Banking Corporation- Series 1463 AUD 40,000,000 FRN Due September 2031 ISIN Number ¦ XS2388390762 ISIN Reference ¦ 238839076 Issue Nomin AUD ¦ 40000000 Period ¦ 12/22/2025 to 3/23/2026 Payment Date 3/23/2026 Number of Days ¦ 91 Rate ¦ 4.4275 Denomination AUD ¦ 1000000 ¦ 40000000 ¦ Amount Payable per Denomination ¦ 11038.42 ¦ 441536.8 ¦ Bank of N...
-
Taco Cabana Doubles Down on Value With New Double Happy Hour
SAN ANTONIO--(BUSINESS WIRE)--Taco Cabana® is debuting an expanded Double Happy Hour, giving guests even more chances to enjoy their favorites at unbeatable prices....
-
Citibank UK Regulatory Announcement: Early Redemption(s)
LONDON--(BUSINESS WIRE)-- Please be advised that the following issue has redeemed early: ISIN: XS2950719158 Issuer: Silverstone Master Issuer Plc Call Date: 21/01/2026 Amount Redeeming: GBP 500,000,000 Call Price: 100%...
-
274 MW d’énergie renouvelable pour le Québec : le Parc éolien de la Madawaska est autorisé
DÉGELIS--(BUSINESS WIRE)--Les partenaires du Parc éolien de la Madawaska — EDF solutions électriques, l’Alliance de l’énergie de l’Est et la Société de gestion éolienne de la Madawaska Inc. (filiale d’Hydro-Québec) — se réjouissent de l’autorisation gouvernementale qui officialise la mise en œuvre future du Parc éolien de la Madawaska. Cette étape marque une avancée majeure et permet de poursuivre les démarches finales d’autorisation et de permis en vue des travaux de construction. Ce projet re...
-
First Cessna SkyCourier Delivered into Mexico, Expanding Air Freight Capabilities for FlexCoah
WICHITA, Kan.--(BUSINESS WIRE)--The first Cessna SkyCourier in Mexico was recently delivered to cargo transportation provider FlexCoah for use by the company’s aviation subsidiary, Altair. The aircraft — a freighter variant — will expand the company’s air freight capabilities throughout the country. The Cessna SkyCourier is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company. “The Cessna SkyCourier’s combination of reliability, payload capacity and mission fle...
-
Mirantis Joins Linux Foundation's Agentic AI Foundation as Silver Member
CAMPBELL, Calif.--(BUSINESS WIRE)--Mirantis announces its official membership in the Linux Foundation's newly formed Agentic AI Foundation (AAIF) as a Silver Member....
-
GenSight Biologics annonce l’autorisation réglementaire de traiter des patients en Israël avec GS010/LUMEVOQ® dans le cadre d’un accès compassionnel
PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, éligible PEA-PME), une société biopharmaceutique spécialisée dans le développement et la commercialisation de thérapies géniques innovantes pour les maladies neurodégénératives de la rétine et les troubles du système nerveux central, annonce aujourd’hui que la Division pharmaceutique du ministère israélien de la Santé a autorisé l’utilisation, dans le pays, de la thérapie génique candidate GS010/...